<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04734418</url>
  </required_header>
  <id_info>
    <org_study_id>REDNIVI</org_study_id>
    <nct_id>NCT04734418</nct_id>
  </id_info>
  <brief_title>Evaluation of Remifentanil and Dexmedetomidine in Patients With Noninvasive Mechanical Ventilation Intolerance</brief_title>
  <official_title>Evaluation of Remifentanil and Dexmedetomidine in Patients With Noninvasive Mechanical Ventilation Intolerance After Cardiac Surgery: a Multicenter, Prospective, Single-blind, Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, NIV(Noninvasive ventilation ) is widely used in patients with hypoxemia and&#xD;
      atelectasis after cardiac surgery.About 15% of patients have intolerance during NIV. The main&#xD;
      manifestation is that the patient feels uncomfortable, often breaks away from the mask, and&#xD;
      even gradually becomes agitated, which eventually leads to the failure of non-invasive&#xD;
      ventilation.The patient's intubation rate is as high as 44%, and the mortality rate is&#xD;
      34%.There are many ways to prevent or treat NIV intolerance, of which the most used is to&#xD;
      sedate the patient. This study aims to evaluate the effects of remifentanil and&#xD;
      dexmedetomidine in the sedation of patients with intolerance to non-invasive mechanical&#xD;
      ventilation after cardiac surgery, and to explore the optimal plan for sedation of patients&#xD;
      with intolerant non-invasive mechanical ventilation after cardiac surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission rate of intolerance in patients with intolerance of non-invasive mechanical ventilation after cardiac surgery after sedation with remifentanil or dexmedetomidine.</measure>
    <time_frame>Within 72 hours of study drug used</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality in both remifentanil and dexmedetomidine group</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation time in both remifentanil and dexmedetomidine group</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic changes in both remifentanil and dexmedetomidine group</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of delirium in both remifentanil and dexmedetomidine group</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days in ICU in both remifentanil and dexmedetomidine group</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intubation rate in both remifentanil and dexmedetomidine group</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tracheotomy rate in both remifentanil and dexmedetomidine group</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">178</enrollment>
  <condition>NIV Intolerance</condition>
  <arm_group>
    <arm_group_label>Remifentanil group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Intravenous pump injection.The initial dose of remifentanil is 0.05 μg/kg/min.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of remifentanil is 0.12 μg/kg/min</description>
    <arm_group_label>Remifentanil group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Intravenous pump injection.The initial dose of dexmedetomidine is 0.5 μg/kg/h.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of dexmedetomidine is 1.0 μg/kg/h.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sign the informed consent form voluntarily and follow the plan requirements;&#xD;
&#xD;
          -  Age from 18 to 75 years old (including 18 and 75 years old), regardless of gender;&#xD;
&#xD;
          -  Patients who received non-invasive mechanical ventilation after cardiac surgery and&#xD;
             were intolerant of non-invasive ventilation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of allergy to any component of the study drug;&#xD;
&#xD;
          -  Visual analogue scale of pain (VAS) score &gt;4；&#xD;
&#xD;
          -  Who had taken dexmedetomidine within 8 hours prior to the study;&#xD;
&#xD;
          -  Who had used remifentanil within 2 hours before the study began;&#xD;
&#xD;
          -  Expectoration difficulties;&#xD;
&#xD;
          -  Women who are pregnant or lactating;&#xD;
&#xD;
          -  Coma or uncontrollable convulsions;&#xD;
&#xD;
          -  Have a history of mental illness or cognitive impairment;&#xD;
&#xD;
          -  Delirium before the study began;&#xD;
&#xD;
          -  Patients with severe liver dysfunction (CTP grade C);&#xD;
&#xD;
          -  Patients with renal insufficiency (patients receiving renal replacement therapy);&#xD;
&#xD;
          -  Preoperative left ventricular ejection fraction (LVEF) &lt; 30%;&#xD;
&#xD;
          -  History of drug and alcohol abuse;&#xD;
&#xD;
          -  Other conditions that the investigator deems inappropriate for participation in this&#xD;
             clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhe Luo, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guo-wei Tu, MD PhD</last_name>
    <phone>13501996995</phone>
    <email>tu.guowei@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guang-wei Hao, MD PhD</last_name>
    <phone>15921488129</phone>
    <email>hao.guangwei@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guo-wei Tu, Doctor</last_name>
      <phone>86-13501996995</phone>
      <email>tu.guowei@zs-hospital.sh.cn</email>
    </contact>
    <investigator>
      <last_name>Guo-wei Tu, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://jtd.amegroups.com/article/view/44501/html</url>
    <description>Remifentanil versus dexmedetomidine for treatment of cardiac surgery patients with moderate to severe noninvasive ventilation intolerance (REDNIVIN): a prospective, cohort study</description>
  </link>
  <results_reference>
    <citation>Hao GW, Luo JC, Xue Y, Ma GG, Su Y, Hou JY, Yu SJ, Liu K, Zheng JL, Tu GW, Luo Z. Remifentanil versus dexmedetomidine for treatment of cardiac surgery patients with moderate to severe noninvasive ventilation intolerance (REDNIVIN): a prospective, cohort study. J Thorac Dis. 2020 Oct;12(10):5857-5868. doi: 10.21037/jtd-20-1678.</citation>
    <PMID>33209418</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 22, 2021</study_first_submitted>
  <study_first_submitted_qc>January 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 2, 2021</study_first_posted>
  <last_update_submitted>March 14, 2021</last_update_submitted>
  <last_update_submitted_qc>March 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Guowei Tu</investigator_full_name>
    <investigator_title>Associated professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

